MedPath

Multi center randomized controlled clinical trial of Xiezhuo Tongluo Formula in the treatment of chronic kidney disease stage 3-4

Phase 1
Not yet recruiting
Conditions
chronic kidney disease
Registration Number
ITMCTR2000003976
Lead Sponsor
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

(1) It met the diagnostic criteria of CKD3-4
(2) Aged 18 to 75 years old and can sign the informed consent form independently
(3) Blood pressure 100-160/60-100mmHg.

Exclusion Criteria

(1) Prepare for renal replacement therapy;
(2) Immunosuppressive therapy were performed;
(3) Patients with acute infection, serious primary diseases of heart, lung, brain, liver and hematopoietic system, diabetic ketoacidosis, malignant tumor, active tuberculosis and psychotic patients;
(4) eGFR fluctuated more than 30% in three months;
(5) Severe hyperkalemia (blood potassium>6.5mmol/L);
(6) Allergy history to some components of the drug used;
(7) Pregnant or during lactation;
(8) Participated in other clinical studies.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Ā© 2025 MedPath, Inc. All rights reserved.